Login / Signup

Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial.

Thomas DörnerMartin KaulAntónia SzántóJui-Cheng TsengAthena S PapasIlona PylvaenaeinenMalika HanserNasri AbdallahAndrea GrioniAida Santos Da CostaEnrico FerreroPeter GergelyRainer HillenbrandAlexandre AvrameasBruno CenniRichard M Siegel
Published in: Annals of the rheumatic diseases (2023)
These data show preliminary efficacy and favourable safety of remibrutinib in a phase 2 trial for SjS.
Keyphrases